🔴 LIVE: The Secrets of ProPicks AI Success Revealed + November’s List FREEWatch Now

Cardinal Health to pay $13 million to resolve U.S. kickback case

Published 01/31/2022, 10:47 AM
Updated 01/31/2022, 11:36 AM
© Reuters. FILE PHOTO: Signage is seen at the United States Department of Justice headquarters in Washington, D.C., U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
CAH
-
ROL
-

By Nate Raymond

BOSTON (Reuters) -Drug distributor Cardinal Health Inc (NYSE:CAH) has agreed to pay more than $13 million to resolve allegations it gave doctors kickbacks to buy pharmaceutical products paid for by federal healthcare programs, the U.S. Justice Department said on Monday.

U.S. Attorney Rachael Rollins (NYSE:ROL) in Boston said the Ohio-based drug distributor violated the False Claims Act by paying kickbacks to physician practices in the form of "upfront discounts."

Cardinal Health acknowledged certain facts as part of the $13.125 million settlement, Rollins' office said, though the company in a statement noted that it did not admit liability as part of the deal.

It said it no longer offers the term-based up-front discounts at issue in the settlement.

The Justice Department said that Cardinal Health since 2013 had made payments to physician practices in advance of them buying any drugs that failed to comply with government restrictions on upfront discount arrangements.

Under the Anti-Kickback Statute, drug distributors are prohibited from offering or paying any compensation to convince doctors to purchase medications for use on patients covered by the government's Medicare health insurance program.

© Reuters. FILE PHOTO: Signage is seen at the United States Department of Justice headquarters in Washington, D.C., U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo

The Office of Inspector General for the U.S. Department of Health and Human Services has said distributors may legally offer commercially available discounts to customers under certain circumstances.

But the department said Cardinal's payments did not meet those requirements because they were not attributable to identifiable sales of pharmaceutical products or purported rebates that the customers had not actually earned.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.